Business
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"text","content":"Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial momentum Management to host conference call today, November 4, 2025, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the third quarter ended September 30, 2025. “Our third quarter results, highlighted by nearly $119 million in XDEMVY sales, reflect the strength of our commercial model, the scale of engagement across eye care, and the impact we’re having on patients,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “We’ve established a new category in eye care, and XDEMVY is now one of the best-selling prescription eye drops. Simultaneously, we are expanding our pipeline with more category-creating programs like ocular rosacea – another widespread condition with significant unmet need – that position Tarsus for sustained, long-term growth. With each new milestone, we are deepening our impact and shaping the future of eye care.” Recent Business and Clinical Highlights XDEMVY is continuing on a strong growth trajectory with Q3 results of: $118.7 million in net product sales.More than 103,000 bottles delivered to patients.Broad, high-quality coverage, with more than 90% of commercial, Medicare and Medicaid lives covered, leading to a gross-to-net discount of 44.7%. Two years into launch, Tarsus is fundamentally changing how eye care professionals (ECPs) diagnose and treat Demodex blepharitis (DB). More than 20,000 ECPs have written multiple prescriptions reflecting growing confidence and the consistent integration of XDEMVY into clinical practice.At the end of Q3 2025, the number of ECPs prescribing more than one bottle per week increased by approximately 30% compared to Q2 2025. Tarsus continues to execute on its category-creation strategy, advancing a robust pipeline designed to establish new treatment categories, with plans to initiate: A Phase 2 study of TP-04 (lotilaner ophthalmic gel) for the potential treatment of ocular rosacea (OR), a highly prevalent and underserved eye disease with no FDA-approved therapy, in December 2025, with topline data expected by year-end 202...